During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide
During pregnancy, this medication should be used only when clearly needed
This format also protects the peptide from oxidation during storage
Nevertheless, the vast majority of published studies rely on subcutaneous injection routes to ensure consistent systemic absorption and biological effect [11]
For example, peptides, especially when injected, may trigger severe immune responses